Home  »  Stocks to Invest   »  Baudax Bio, Inc. (BXRX) Stock Climbing in Aftermar...

Baudax Bio, Inc. (BXRX) Stock Climbing in Aftermarket, Here’s the Reason

Baudax Bio, Inc. (BXRX), a pharmaceutical company, has increased 6.32% in aftermarket trading session. As a result, BXRX is trading at $0.56 at the time of the writing. The increase could be attributable to the upcoming announcement of quarterly results by the company. On Friday, BXRX closed the day at $0.52 after declining 7.74% during regular trading hours.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Why BXRX increase?

On 28th October, BXRX announced that it would report third-quarter 2021 financial results on November 4th, 2021. It further said that the management of the company would host the conference call as well to discuss the financial results and the recent operational highlights.

Approval of inducement grants

On 1st October, BXRX announced that the compensation committee of its Board of Directors had approved inducement grants of stock options for the purchase of an aggregate of 242,688 shares of the company’s common stock and restricted stock units which covered 79,385 shares of the company’s common stock to 22 newly hired employees. The grant date was 30th September 2021.

Q2 2021 financial results

On 5th August, BXRX reported the financial results for the second quarter of the fiscal year 2021. The quarter ended on 30th June 2021. The company had cash and cash equivalents of $37.6 million on 30th June. The total revenue generated by the company for the period was $0.2 million as compared to $0.3 million for the same period of 2020. The cost of sales for the three months was $0.6 million against $0.7 million for the same period of 2020. R&D expenses for the three months were $0.9 million against $1.4 million for the same period of 2020. The selling, general and administrative expenses for the period were $10.6 million against $11.2 million for the same period of 2020. The company reported a net loss of $15.3 million (or $0.21 per diluted share) against $30.4 million (or $1.72 per diluted share) for the same period of 2020.

Executive commentary

While commenting on the results, Gerri Henwood, President and CEO of BXRX said that the company is pleased to see outstanding results for the quarter. He further said that the company is looking forward to further improving its performance in near future.

What’s ahead for BXRX?

During the previous half-year, BXRX declined more than 50%. The recent quarterly results and business expansion strategies, however, have marked drastic improvements in this regard. Analysts hope that the continuation of current policies would reap numerous dividends for BXRX in near future.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam